No abstract

No abstract

There are many ongoing randomised trials of promising therapies for metastatic hormone sensitive prostate cancer (mHSPC), but standard systematic reviews may not synthesise these in a timely or reliable way. We demonstrate how a novel approach to evidence synthesis is being used to speed up and improve treatment evaluations for mHSPC. This more prospective, dynamic and collaborative approach to systematic reviews of both trial results and individual participant data (IPD) is helping to establish quickly and reliably which treatments are most effective, and for which men. However, mHSPC is a complex disease and trials can be lengthy. Thus, parallel efforts will synthesise further IPD to identify early surrogate endpoints for overall survival and prognostic factors, to reduce the duration of and improve the design of future trials. The STOPCAP M1 repository of IPD will be made available to other researchers for tackling new questions arising. The associated global, collaborative forum will aid strategic and harmonised development of the next generation of mHSPC trials (STOPCAP M1; http:\\www.stopcapm1.org).